




---

# PRODUCT PORTFOLIO

2025-2026



# Product Portfolio

| PRODUCT                                        | PHARMACEUTICAL FORM                 | STRENGTHS                                        | THERAPEUTIC INDICATIONS                                                 |
|------------------------------------------------|-------------------------------------|--------------------------------------------------|-------------------------------------------------------------------------|
| Rosuvastatin + Ezetimibe                       | Film coated tablets                 | (5+10) mg, (10+10) mg<br>(20+10) mg, (40+10) mg  | Treatment of high cholesterol and triglyceride levels                   |
| Rosuvastatin + Ezetimibe<br><i>value-added</i> | Film coated tablets                 | (15+10) mg<br>(30+10) mg                         | Treatment of high cholesterol and triglyceride levels                   |
| Atorvastatin + Ezetimibe                       | Double layer<br>Film coated tablets | (10+10) mg, (20+10) mg<br>(40+10) mg, (80+10) mg | Treatment of high cholesterol and triglyceride levels                   |
| Bempedoic Acid                                 | Film coated tablets                 | 180 mg                                           | Hypercholesterolaemia and mixed dyslipidaemia<br>Cardiovascular disease |
| Bempedoic Acid + Ezetimibe                     | Film coated tablets                 | 180 mg + 10 mg                                   | Hypercholesterolaemia and mixed dyslipidaemia<br>Cardiovascular disease |
| Dapagliflozin                                  | Film coated tablets                 | 5 mg<br>10 mg                                    | Antidiabetic<br>Heart failure<br>Chronic kidney disease                 |
| Dapagliflozin<br><i>value-added</i>            | Oral solution                       | 5 mg/ 5 mL                                       | Antidiabetic<br>Heart failure<br>Chronic kidney disease                 |
| Dapagliflozin + Metformin                      | Film coated tablets                 | 5 mg + 850 mg<br>5 mg + 1000 mg                  | Antidiabetic                                                            |
| Apixaban                                       | Tablets                             | 2,5 mg<br>5 mg                                   | Prevention of venous thromboembolic events<br>Anticoagulant             |
| Apixaban<br><i>value-added</i>                 | Oral suspension                     | 5 mg/ 5 mL                                       | Prevention of venous thromboembolic events<br>Anticoagulant             |

| PRODUCT                                         | PHARMACEUTICAL FORM                 | STRENGTHS                                            | THERAPEUTIC INDICATIONS                                                   |
|-------------------------------------------------|-------------------------------------|------------------------------------------------------|---------------------------------------------------------------------------|
| <b>Lisdexamfetamine</b>                         | Capsules                            | 10 mg<br>20 mg, 30 mg, 40 mg<br>50 mg, 60 mg & 70 mg | Attention Deficit<br>Hyperactivity Disorder<br>(ADHD)                     |
| <b>Lisdexamfetamine</b><br><i>value-added</i>   | Oral solution                       | 10 mg/1 mL                                           | Attention Deficit<br>Hyperactivity Disorder<br>(ADHD)                     |
| <b>Cholecalciferol</b>                          | Hard capsules                       | 10,000 IU<br>25,000 IU                               | Treatment or prevention of<br>vitamin D3 deficiency                       |
| <b>Carbocisteine</b><br>(Sugar free)            | Oral solution                       | 250 mg/ 5 mL                                         | Adjunctive therapy of<br>respiratory tract<br>disorders Mucolytic         |
| <b>Magnesium<br/>aspartate</b>                  | Oral solution                       | 24,3 mg/1 mL                                         | Treatment or prevention of<br>low levels of Magnesium                     |
| <b>Sodium fluoride</b>                          | Toothpaste                          | 2,800 ppm<br>5,000 ppm                               | Prevention of dental<br>caries                                            |
| <b>Diclofenac sodium<br/>+ Thiocolchicoside</b> | Injection solution                  | (75+4) mg                                            | Treatment of pain due to<br>muscle spasm                                  |
| <b>Thiamine</b>                                 | Injection solution                  | 250 mg/ 5 mL                                         | Treatment or prevention of<br>vitamin B1 deficiency                       |
| <b>Fosfomycin</b>                               | Powder for solution<br>for infusion | 2 g, 3 g, 4 g<br>5 g, 8 g                            | Antibiotic                                                                |
| <b>Netupitant +<br/>Palonosetron</b>            | Hard capsules                       | 300 mg + 0.5 mg                                      | Prevention of nausea<br>associated with emetogenic<br>cancer chemotherapy |

# **Bridging data to compile unique products**

- Out-licensing of own IP
- Robust supply chain
- Product development
- Regulatory approval
- Life cycle management